Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug AMG 436 targets tough cancers in early trial

NCT ID NCT07403721

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called AMG 436, alone or with other cancer treatments, in adults with advanced solid tumors that have high microsatellite instability or mismatch repair deficiency. The main goals are to check safety, find the best dose, and see how the drug moves through the body. About 464 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AMG 436

What this could lead to

If successful, this could lead to a new treatment option for people with hard-to-treat cancers that have specific genetic features.

What could go wrong

This is an early phase 1 trial focused on safety and dosing, so it is unknown if AMG 436 will effectively shrink tumors or improve survival. Side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC OR LOCALLY ADVANCED SOLID TUMORS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCHED REPAIR DEFICIENCY (DMMR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC OR LOCALLY ADVANCED SOLID TUMORS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCHED REPAIR DEFICIENCY (DMMR)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aichi Cancer Center

    RECRUITING

    Nagoya, Aichi-ken, 464-8681, Japan

  • Calvary Mater Newcastle Hospital

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • City of Hope Orange County Lennar Foundation Cancer Center

    RECRUITING

    Irvine, California, 92618, United States

  • Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Midwestern Regional Medical Center dba City of Hope Chicago

    RECRUITING

    Zion, Illinois, 60099, United States

  • National Cancer Center Hospital

    RECRUITING

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa-shi, Chiba, 277-8577, Japan

  • New England Cancer Specialists

    RECRUITING

    Westbrook, Maine, 04092, United States

  • Next Oncology - Dallas

    RECRUITING

    Irving, Texas, 75039, United States

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 1Z5, Canada

  • Sun Yat-Sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510663, China

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 11217, Taiwan

  • Tennessee Oncology PLLC

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    RECRUITING

    Koto-ku, Tokyo, 135-8550, Japan

  • Universitair Ziekenhuis Gent

    RECRUITING

    Ghent, 9000, Belgium

  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc

    RECRUITING

    Brussels, 1200, Belgium

  • Zhongshan Hospital Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China